In vitro studies show that using CCL5-neutralizing antibodies can abolish the resistance of AML cells with FLT3 mutations to FLT3 tyrosine kinase inhibitors, suggesting CCR5 or its ligands as convenient therapeutic targets. The gene discussed is CCR5; the disease is acute myeloid leukemia.